Novocure Ltd Stock
Your prediction
Novocure Ltd Stock
A loss of -2.280% shows a downward development for Novocure Ltd.
For the coming years our community has positive and negative things to say abot the Novocure Ltd stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -2.280% | 2.224% | 8.635% | -61.544% | -61.332% | -84.916% | -91.963% |
| Ironwood Pharmaceuticals | -0.740% | -10.067% | -0.741% | -37.383% | -36.190% | -76.716% | -72.653% |
| Iovance Biotherapeutics Inc. | -0.280% | 25.933% | 22.910% | -66.564% | -65.306% | -57.442% | -94.118% |
| Alnylam Pharmace. | -2.390% | 1.593% | -10.744% | 45.419% | 49.668% | 50.100% | 197.361% |
News
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable
Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and